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NOVA1 regulates hTERT splicing and cell growth
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Alternative splicing is dysregulated in cancer and the reactivation of telomerase involves the
splicing of TERT transcripts to produce full-length (FL) TERT. Knowledge about the splicing
factors that enhance or silence FL hTERT is lacking. We identiﬁed splicing factors that reduced
telomerase activity and shortened telomeres using a siRNA minigene reporter screen and a
lung cancer cell bioinformatics approach. A lead candidate, NOVA1, when knocked down
resulted in a shift in hTERT splicing to non-catalytic isoforms, reduced telomerase activity,
and progressive telomere shortening. NOVA1 knockdown also signiﬁcantly altered cancer cell
growth in vitro and in xenografts. Genome engineering experiments reveal that NOVA1
promotes the inclusion of exons in the reverse transcriptase domain of hTERT resulting in the
production of FL hTERT transcripts. Utilizing hTERT splicing as a model splicing event in
cancer may provide new insights into potentially targetable dysregulated splicing factors in
cancer.
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Telomerase is a tightly regulated ribonucleoprotein complex(RNP) that maintains or lengthens human telomeres byadding 5′-TTAGGG repeats. Telomerase consists mini-
mally of a reverse transcriptase (RT) protein catalytic subunit
(hTERT) and a template RNA, telomerase RNA (hTERC1).
Embryonic and transit amplifying stem cells have telomerase
activity while most somatic cells do not. However, 85–90% of
cancers utilize telomerase activity to maintain telomeres2. In most
human cancers, the limiting factor in telomerase activity is the
expression level of the RT, hTERT. hTERT is regulated by tran-
scriptional and post-transcriptional mechanisms3–5. Transcrip-
tional regulation of hTERT has been extensively studied, however
the ﬁndings do not completely explain how telomerase is regu-
lated in cancer. How the transcribed messenger RNA is processed
(i.e., RNA-processing events), which is critical for determining if
active telomerase is produced or not, is less well understood. One
such RNA-processing regulatory mechanism is alternative spli-
cing, which contributes to protein diversity and transcript
abundance6. hTERT produces a transcript containing 16 exons
that can be spliced into multiple isoforms7–10, including the full-
length (FL) RT competent form. In tumor cells and dividing stem
cells, FL hTERT and several spliced variants are co-expressed at
detectable levels. Since telomerase activity is almost universally
activated in human cancer, further research into the mechanisms
that regulate hTERT mRNA processing, speciﬁcally alternative
splicing, may provide additional clues about telomerase regula-
tion in cancer and importantly could elucidate new candidate
genes to target for telomerase inhibition and for anticancer
therapies.
Of the hTERT splice isoforms, the four major isoforms that
have been studied involve exons 5–9, which encode the RT
domain of hTERT (Supplementary Table 1, Supplementary Fig-
ure 6). The four major isoforms are a result of splicing of regions
termed “alpha” and “beta” located within exons 5–910. Only the
“FL” version (α+β+; FL) containing all ﬁve intact exons of the
RT domain has the potential to encode catalytically active
enzyme8,10,11. The other isoforms are generated by skipping of
exons 7 and 8 (α+β−; minus beta), which introduces a frameshift
and premature stop codon in exon 10, the skipping of 36
nucleotides (nts) of exon 6 (α−β+; minus alpha), which is in
frame and generates a dominant-negative RT incompetent telo-
merase10, and (α−β−; minus alpha-beta), which has both skip-
ping events (10; Supplementary Table 1). Other variants of hTERT
exist that result from splicing events outside of the RT domain12
(Supplementary Table 1). The important regulatory sequences
and splicing factors that bind hTERT pre-mRNAs to produce the
RT competent versus RT-deﬁcient hTERT splice isoforms are not
well described.
Very few investigations into the cis- and trans-acting factors
that regulate splicing of hTERT have been performed. Our group
previously identiﬁed highly conserved sequences in old world
primates, including humans, that regulate hTERT splicing
choice13,14. However, little is currently known about the trans-
acting factors that bind these regulatory regions. Thus, identiﬁ-
cation of such proteins would close a signiﬁcant gap in telomerase
regulation knowledge and also potentially identify protein targets
to shift the splicing of hTERT message to inactive forms to reduce
telomerase activity, progressively shorten telomeres, and ulti-
mately leading to reduced tumor growth in vivo. RNA-binding
proteins target multiple genes; thus, it is likely that identiﬁcation
of a protein that targets hTERT may impact other important
pathways that are cancer cell dependencies.
Recently, three splicing proteins, SRSF11, hnRNPL, and
hnRNPH2, when overexpressed in cancer cells were identiﬁed to
potentially regulate hTERT minus beta splicing choice using an
hTERT minigene15. There are more than 500 RNA-binding
proteins encoded in the genome and splicing is the result of
cellular context, RNA secondary structure, RNA editing, and
competition for splice sites, therefore much is left to be learned
concerning hTERT splicing regulation16–18.
To address the protein networks that regulate the alternative
splicing of FL hTERT in cancer cells, we took two approaches: a
hTERT dual-luciferase minigene splicing reporter RNAi screen
and a bioinformatic analysis of a panel of highly characterized
human lung cancer cell lines to identify genes that may regulate
hTERT splicing and other cancer cell phenotypes. These two
approaches identiﬁed neuro-oncological ventral antigen 1
(NOVA1) as a candidate gene. In non-small cell lung cancer cells
that express high levels of NOVA1, we found that stable reduc-
tion in NOVA1 levels shifted hTERT splicing toward inactive
transcripts, reduced telomerase activity, which led to progres-
sively shortened telomeres. We also demonstrated that NOVA1
knockdown reduced migration through extracellular matrices,
and resulted in smaller tumors in vivo. Thus, the experiments
described in the present report provide a mechanistic view of how
cancer cells regulate hTERT splicing.
Results
hTERT minigene small interfering RNA screen of RNA-
binding proteins. To investigate the protein factors involved in
alternative splicing of hTERT we performed a small interfering
RNA (siRNA) screen in HeLa cells stably expressing an hTERT
minigene splicing reporter (Fig. 1). The minigene used in this
study allowed for luciferase-based measurements of hTERT “FL”
(intact exons 6–8) and minus beta hTERT (skipping of exons 7
and 8). Fluc indicates minus beta splicing (inactive hTERT) and
FL hTERT is indicated by Rluc (Fig. 1a).
We obtained pools of four siRNAs to 516 RNA-binding
protein genes. HeLa cells containing the minigene reporter were
transfected with the siRNAs and luciferase measurements were
made 72 h later (Fig. 1a). The screen repeat runs were highly
correlated (R2= 0.794, Pearson’s r, Supplementary Figure 1C). Of
the 528 siRNAs tested, 97 siRNAs targeting 93 unique genes
resulted in a twofold or greater increase in minus beta splicing
and 20 siRNAs targeting 17 genes resulted in a twofold or greater
increase in FL splicing (a list of these gene identiﬁers can be
found in Supplementary Data ﬁle 1). Our objective was to ﬁnd
targets that had cancer speciﬁcity (i.e., not widely or highly
expressed across normal adult human tissues) for potential
follow-up studies; thus, we focused our follow-up studies on the
93 genes that when knocked down resulted in twofold or greater
increases in the ratio of minus beta to FL. We pursued a parallel
bioinformatics approach to narrow down the list of candidate
genes using a highly characterized panel of human non-small cell
lung cancer cell lines.
Bioinformatics analysis of 516 RNA-binding proteins. We
measured telomere biology phenotypes (telomerase activity,
hTERT expression, and telomere length19) in 17 well-
characterized lung cancer cell lines and correlated expression of
splicing factors and telomere biology between these cell lines to
narrow down our target gene list (Supplementary Figure 1D,
Supplementary Figure 1E). We found that telomere length and
telomerase activity were signiﬁcantly correlated (R2= 0.51, p=
0.001, Pearson’s r, Supplementary Figure 1G). hTERT mRNA
expression of exons 7/8 and exons 15/16 showed a modest but
signiﬁcant correlation with telomere length (R2= 0.38, p= 0.008
for exons 7/8 and R2= 0.30, p= 0.02 for exons 15/16, Pearson’s r;
Supplementary Figure 1H). Telomerase activity correlated with
exons 7/8 expression of hTERT (R2= 0.27, p= 0.03, Pearson’s r;
Supplementary Figure 1I). We quantiﬁed hTERT splice isoforms
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(Fig. 1b, primer sequences are in Supplementary Table 2), we
choose to analyze cell lines that differed signiﬁcantly by the
percentage of FL hTERT expression, percentage of minus beta
hTERT expression, and telomerase activity (three lines at each
extreme, Fig. 1c, “Gene Discovery Data set”). We correlated the
expression data of 516 RNA-binding proteins across six cell lines
(differential expression analysis (t tests), false-discovery rate
corrected with Benjamini-Hochberg procedure) to the amount of
potential FL hTERT as measured by our splice isoform assays.
This analysis revealed 12 genes whose expression signiﬁcantly
correlated to the amount of FL hTERT (heatmap shows differ-
ential expression of the 12 genes that correlated to hTERT
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expression in 6 non-small cell lung cancer cell lines; Fig. 1c). Of
these 12 genes, 4 genes overlapped with the 93 genes that also
changed (twofold increase in reporter minus beta hTERT signal
compared to control) in the minigene screen (SNRPB, NOVA1,
U2AF2, and CDC40). NOVA1 was the top-ranking tissue-speciﬁc
RNA-binding protein associated with cancer20,21, and in silico
analysis revealed binding sites for NOVA1 within the hTERT
locus. Of the 37 proteins that had a greater impact on switching
hTERT splicing in the minigene assay, NOVA1 was the only
factor with an expression proﬁle that was not ubiquitous indi-
cating the potential for therapeutic targeting. Thus, NOVA1 was
chosen for further analysis.
We hypothesized that NOVA1 may mark a network of splicing
factors related to high levels of hTERT FL mRNA22. Hierarchical
clustering analysis (divisive) was used to separate and prioritize
cell lines based on telomerase biology (log2-transformed
telomerase and percentage of FL hTERT) and expression of
NOVA1 mRNA (log2-transformed as measured by droplet digital
PCR (ddPCR)). Using two groups of cell lines (seven cell lines
total: four with high telomerase, percentage of FL hTERT,
NOVA1 compared to three low telomerase, percentage of FL
hTERT, and NOVA1) we compared the expression proﬁles of the
516 RNA-binding proteins and splicing factors (dendrogam of
hierarchical clustering analysis of cell lines Supplementary
Figure 1I). This expression analysis revealed 22 genes with
different expression patterns between the two groups of lung
cancer cell lines (Fig. 1d; heatmap for “Network Discovery Data
set”). Next, we probed the overlapping genes between this gene
list (22) and the minigene list (93) and observed that 7 genes
overlapped (SNRPD2, CWC22, NOVA1, RBM10, ZMAT2, SLU7,
and FAM131B). Ten genes came out in at least two of the three
screens and caused a twofold or greater change in the minigene
reporter screen (Supplementary Figure 1J; Supplementary Data
ﬁle 1 shows tabulated results of all three screens, siRNA
sequences, and the overlap analyses).
NOVA1 protein was not expressed in normal human bronchial
epithelial cells (HBECs), and was overexpressed in 71% of our
lung cancer cell lines (12 of 17 lines; Fig. 1e, Supplementary
Figure 1F). We correlated the expression of NOVA1 mRNA and
protein to the percentage of hTERT FL mRNA and observed a
signiﬁcant correlation in both cases (Pearson’s r, R2= 0.25, p=
0.039 for mRNA; R2= 0.34, p= 0.01 for protein; Supplementary
Figure 1L and M, respectively). NOVA1 mRNA expression and
NOVA1 protein expression were signiﬁcantly correlated in our
non-small cell lung cancer cell lines (R2= 0.50, p= 0.001,
Pearson’s r; Supplementary Figure 1N). We also measured the
expression of NOVA1 mRNA in a panel of human adult and fetal
tissues, observing low expression in tissues with the exception of
brain (as expected), reproductive (testis), and fetal organs
(Fig. 1f).
To conﬁrm the results of the minigene screen and the
bioinformatics correlation analysis, we performed short-term
siRNA knockdown experiments (Fig. 1g, h). hTERT potential FL
mRNA levels were reduced by 60% in H1299 and 50% in H920
cells treated with NOVA1 siRNAs compared to cells treated with
control non-targeting siRNAs (Fig. 1g). Telomerase enzyme
activity was reduced in NOVA1-depleted cells by 2-fold (p= 0.05,
Student’s t) and 2.5-fold (p < 0.05, Student’s t) in H1299 and
H920 cells, respectively compared to control siRNA-treated cells
(Fig. 1h23. Knockdown of NOVA1 was conﬁrmed in both cell
lines (Supplementary Figure 1O). Importantly, hTERT steady-
state transcripts (exons 15/16) were not signiﬁcantly decreased by
transient knockdown of NOVA1 in either cell line (Supplemen-
tary Figure 1P), indicating that NOVA1 knockdown results in a
change in splicing and not just a downregulation in transcrip-
tional rate, which is known to affect splicing24. We did observe a
reduction in exon 7/8 containing transcripts, conﬁrming the
reduction in potential FL (Supplementary Figure 1P). These data
together with the minigene and bioinformatics analyses support
that NOVA1 is a key member of a potential network of genes
regulating hTERT alternative splicing.
Long-term depletion of NOVA1 shifts hTERT splicing. Since its
initial description, NOVA1 (Ri-antigen) has been observed to be
overexpressed in neuro-endocrine cancers such as breast, lung,
and brain cancers20,21,25–27. NOVA1 contains three K-homology
domains and binds RNA at YCAY (Y=C or T) clusters com-
monly found though out the genome (1 in 64 nts)28,29. NOVA1
YCAY RNA-binding motifs are found in hTERT introns and
exons. We knocked down NOVA1 in three different cell lines:
two that express NOVA1 (H1299 and H920) and one that does
not express NOVA1 (Calu6, as a control for off-target effects of
the short hairpin RNA (shRNA) sequence). Stable knockdown of
NOVA1 reduced telomere length and telomerase activity in the
two cell lines that express NOVA1 (Fig. 2a, H1299 cells, Sup-
plementary Figure 2A). NOVA1 protein and mRNA levels were
reduced by about 50% (Fig. 2c, Supplementary Figure 2D).
NOVA1 knockdown reduced the proportion of FL hTERT mes-
sage (Fig. 2b; Supplementary Figure 2B) and decreased telomerase
activity about 50% (p= 0.05, Student’s t, Fig. 2d; Supplementary
Figure 2C), which was sufﬁcient to reduce telomere length in both
H1299 and H920 cells. The >50% telomerase activity reduction
observed leading to progressive telomere shortening is consistent
with human diseases of hTERT haploinsufﬁciency that also result
in clinically signiﬁcant shortened telomeres. The long-term
depletion of NOVA1 also reduced the steady-state transcript
levels of hTERT (Fig. 2d, Supplementary Figure 2E). To
demonstrate that the shRNA was on target for NOVA1, we
transduced H1299 cells with a retroviral 6X MYC-tagged cDNA
construct coding for FL NOVA1 with the shRNA seed sequence
Fig. 1 hTERT alternative splicing is regulated by a network of RNA-binding proteins. a TERT minigene reporter construct and products. CMV: human
cytomegalovirus immediate-early enhancer and promoter, Bp: base pair, B6: variable nucleotide repeat in intron 6 from ref. 13, DR6 and DR8: direct repeat 6
or 8, respectively, from ref. 13, BGH polyA: signal bovine growth hormone polyadenylation signal. b hTERT steady-state isoform/splicing proﬁle in non-small
cell lung cancer cell lines (n= 3). c Differential expression analysis of splicing factors that correlated with high hTERT full-length expression in six non-small
cell lung cancer cell lines. Log2 fold change in gene expression between the cell lines. CLK3 and SNRPB appear twice in the heatmap because two different
microarray probes were differentially expressed between the high hTERT and low hTERT lines. d Differential expression analysis of splicing factors related to
hTERT full-length expression, telomerase activity, and NOVA1 mRNA expression in the seven non-small cell lung cancer cell lines. Log2 fold change in gene
expression between the cell lines. e Expression of NOVA1 protein and histone H3 protein in normal (HBECs) and cancerous lung cell lines. Representative
western blot images are shown (n= 3). f Expression of NOVA1 mRNA by RT-ddPCR in a panel of human fetal and adult tissues. RT reverse transcription,
ddPCR droplet digital PCR (n= 3). g siRNA knockdown of NOVA1 in H1299 and H920 lung cancer lines shifts hTERT splice isoform proportions as
determined using RT-ddPCR (n= 6). h siRNA knockdown of NOVA1 in H1299 and H920 lung cancer lines reduces telomerase activity per cell equivalent
(50 cell equivalents, n= 6, Student’s t test set at *p < 0.05 for signiﬁcance). Data are expressed as means and standard error of the mean where
applicable. Supplementary data associated with this ﬁgure can be found in Supplementary Figure 1
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mutated. The shRNA-resistant NOVA1 cDNA was able to rescue
hTERT splicing changes, transcript levels, and telomerase enzyme
activity (Fig. 2b, d, e). These experiments show that NOVA1 is
mechanistically linked to hTERT and that the observed pheno-
types associated with knockdown are on target. Further, targeting
NOVA1 resulted in a potent effect on hTERT, not only by shifting
the splicing away from FL hTERT transcripts but also by reducing
overall hTERT transcription, which is a different observation
compared to the transient siRNAs. The reduced overall hTERT
mRNA levels are important to consider with recent data indi-
cating that hTERT may have non-canonical roles30,31. To explain
how the NOVA1 rescue returned hTERT transcript levels to
control values, one possibility is that the increased levels of
hTERT (Fig. 2d) is due to a transcription factor being spliced or
another upstream event that NOVA1 is involved in that results in
increased expression of hTERT. Recent RNA-sequencing data
indicate that NOVA1 may regulate the expression of transcrip-
tion factors that could be acting upstream of hTERT in cancer
cells32.
To determine the effects on cell growth of knocking NOVA1
down in non-transformed lung cells, we introduced control (non-
silencing) and NOVA1 shRNAs into HBECs and observed no
signiﬁcant growth defect (Supplementary Figure 2M). To further
determine the effects of NOVA1 reduction on normal cell growth,
we used a siRNA treatment strategy to signiﬁcantly reduce
NOVA1 expression in a normal diploid ﬁbroblast cell strain (BJ
ﬁbroblasts). Over the course of the experiment there was no
inhibition in growth or viability of the BJ ﬁbroblasts treated with
NOVA1 siRNAs compared to control-treated siRNAs (Supple-
mentary Figure 2O and P). The siRNA-induced knockdown of
NOVA1 at both the protein (Supplementary Figure 2Q) and
mRNA level was signiﬁcantly reduced compared to control-
treated cells (Supplementary Figure 2R).
We attempted to knockout NOVA1 with CRISPR/Cas9
genome-editing methods in H1299 lung cancer cells but were
unable to obtain survival clones, suggesting that NOVA1 may be
critical in cell survival pathways in H1299 lung cancer cells.
When we knocked down NOVA1 with shRNAs in H2882,
another non-small cell lung cancer cell line, the cells only divided
twice in 90 days following selection (Supplementary Figure 2S).
H2882 cells have very robust levels of NOVA1 (Fig. 1e), adding
strength to the idea that NOVA1 may be a critical gene to cancer
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Fig. 2 Long-term reduction of NOVA1 progressively shortens telomeres. a Terminal restriction fragment length (TRF-Southern blot) analysis of control
shRNA or NOVA1 shRNA at two population doublings (PD). b Rescue of shRNA knockdown of NOVA1 with a shRNA mutant cDNA in H1299 cells (stable
cell lines were measured a minimum of six times over several passages). hTERT splicing was determined with RT-ddPCR assays. c Western blot of NOVA1
shRNA rescue in H1299 cells (representative image of stable cell lines, measured three times over three passages in culture). d hTERT expression in rescue
H1299 cells as determined by RT-PCR of exons 5–9 (representative image; n= 3). e Rescue of shRNA knockdown of NOVA1 with a shRNA mutant cDNA
partially restores telomerase activity in H1299 cells (n= 6). Telomerase activity was determined with droplet digital TRAP (ddTRAP with 50 cell
equivalents added to the assay). Student’s t test set at *p < 0.05 for signiﬁcance. f Western blot of V5-tagged NOVA1 expression in Calu6 cells
(representative image of stable cell lines). g hTERT splicing proﬁle in Calu6 cells with and without NOVA1 (n= 6). hTERT splicing was determined with RT-
ddPCR assays. h Telomerase enzyme activity (ddTRAP with 50 cell equivalents added to the assay) in Calu6 cells with and without NOVA1 (n= 3).
Student’s t test set at *p < 0.05 for signiﬁcance). Data are expressed as means and standard error of the mean where applicable. *p < 0.05. RT: reverse
transcription, ddPCR: droplet digital PCR. + indicates presence of shRNA or cDNA construct. − indicates absence of shRNA or cDNA construct
(b, d, e). Supplementary data associated with this ﬁgure can be found in Supplementary Figure 2
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cell survival. We observed that a different shRNA targeting
NOVA1 in H1299 cells signiﬁcantly slowed growth and/or was
rapidly silenced (Supplementary Figures 2T and U).
Expression of NOVA1 in cancer cells shifts hTERT splicing. To
determine if expression of NOVA1 in a NOVA1-negative cancer
cell line promotes hTERT FL splicing and increases in telomerase
activity, we transduced Calu6 cells with a lentiviral vector con-
taining a V5-C terminus-tagged NOVA1 FL cDNA. Over-
expression of NOVA1 with both tagged (V5 epitope antibody)
and N terminus NOVA1 antibodies (Fig. 2f) was conﬁrmed.
Telomerase activity increased twofold (p= 0.05, Student’s t,
Fig. 2h) as did the proportion of hTERT FL transcripts (23% vs.
50%; Fig. 2g) in NOVA1-expressing cells compared to control
empty vector cells. In these experiments, telomere length was
slightly elongated by overexpression of NOVA1 (Supplementary
Figure 2N) in line with the NOVA1 knockdown data.
NOVA1 knockdown reduces cancer cell growth phenotypes.
We assayed the tumorigenic properties of NOVA1 knockdown
cells. NOVA1 has a known role in breast and lung cancers33 and is
important during normal development for growth, survival,
migration, and apoptosis32,34,35. NOVA1 knockdown H1299 cells
at population 50 formed signiﬁcantly fewer colonies compared to
control and NOVA1 rescue cells (p < 0.05, Student’s t, Fig. 3a).
NOVA1 knockdown H1299 cells did not invade as efﬁciently as
H1299 shRNA control cells or the NOVA1 rescue H1299 cells using
Boyden chamber assays (p < 0.05, Student’s t, Fig. 3b). Finally, in a
colony formation assay we observed that NOVA1-depleted H1299
cells formed fewer colonies compared to control shRNA H1299
cells and rescue cells (p < 0.05, Student’s t, Supplementary Figure 3).
We also assayed cancer growth phenotypes in a second cell line
after 50 population doublings, H920, and both anchorage-
independent growth and invasive phenotypes were signiﬁcantly
reduced in NOVA1-depleted cells compared to control shRNA cells
(Fig. 3a, b; p < 0.05, Student’s t). Interestingly, the levels or amount
of NOVA1 in the cell lines (H1299 moderate NOVA1 compared to
high levels of NOVA1 in H920 cells) seems to correlate the
response of the cells to knockdown of NOVA1. For instance, the
impact of NOVA1 knockdown on colony formation and migration
was much greater in H920 cells compared to H1299 cells. In Calu6
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Soft agar colony formation is reduced by NOVA1 KD in H1299 and H920 cells. Invasion through matrigel is reduced by NOVA1 KD in H1299 and H920 cells.
Tumor growth is significantly reduced
by NOVA1 KD in H920 cells xenograft.
Tumor growth is significantly reduced by 
NOVA1 KD in H920 cells xenograft.
Tumor growth is significantly increased in NOVA1 expressing tumor
compared to control
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Fig. 3 Manipulation of NOVA1 in cancer cells alters xenograft tumor growth. a Knockdown of NOVA1 in H1299 and H920 cells reduced anchorage-
independent cell growth compared to controls (soft agar colony formation assays, n= 3 for each condition and cell line). + indicates presence of shRNA or
cDNA construct. − indicates absence of shRNA or cDNA construct. b Knockdown of NOVA1 in H1299 and H920 cells reduced migration through an
extracellular matrix (Boyden Chamber assay) compared to controls (n= 3 for each condition and cell line). + indicates presence of shRNA or cDNA
construct. − indicates absence of shRNA or cDNA construct (a, b). c Knockdown of NOVA1 in H920 cells signiﬁcantly reduced xenograft growth compared
to controls. Left panel shows representative images of the hind quarters of nude mice. d Growth curves of xenograft tumors during the experiment (n= 4
injections for each condition, 2 mice per condition). e Expression of NOVA1 in Calu6 cells results in larger xenograft tumors compared to Calu6 controls (a
non-small cell lung cancer cell line lacking NOVA1 expression). Left panel shows representative images of tumors from Calu6 and Calu6 plus NOVA1. Same
stable cell line as used in Fig. 2 and Supplementary Figure 2. f Right panel shows growth curves of xenograft tumors during the experiment (n= 6 injections
for each condition, 3 mice per condition). Data are expressed as means and standard error of the mean where applicable. All tests shown are Student’s
t test set at *p < 0.05 for signiﬁcance. KD: knockdown. Note—an error bar on the controls of a–c was calculated by ﬁrst generating the mean of the controls
and expressing each control relative to this value. We then calculated a standard deviation and standard error based on the variance observed between
these normalized values. Supplementary data associated with this ﬁgure can be found in Supplementary Figure 3
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cells, which lack NOVA1 expression, we observed no differences in
anchorage-independent growth, invasion, or colony formation
between NOVA1 shRNA cells and control shRNA cells, indicating
that these effects were due to on-target effects of the shRNA
(Supplementary Figure 3).
To directly test if the growth phenotypes observed with
NOVA1 knockdown were due to changes in telomere length or
telomerase expression, we attempted to rescue the NOVA1
knockdown by expression of an hTERT cDNA. We introduced an
hTERT cDNA (pMIN-Ub-IRES-Blast lentiviral vector from
ref. 36) into H1299 cells that either already had control shRNA
or NOVA1 shRNA and were cultured for 50 population
doublings. In the H1299 cells with control shRNAs or
NOVA1 shRNAs, we conﬁrmed overexpression of hTERT at
the mRNA level (Supplementary Figures 3D and E) and increased
telomerase activity in the hTERT-transduced cells (Supplemen-
tary Figure 3F). Additionally, we introduced NOVA1 and control
shRNAs into U2OS cells, which do not depend on telomerase to
maintain telomeres but rather use alternative lengthening (ALT)
of telomeres to maintain telomeres. Post selection, these cells were
expanded and assayed to assess the impact of NOVA1 knock-
down on growth independent of telomere length changes. We
conﬁrmed NOVA1 knockdown in the U2OS cells (Supplemen-
tary Figure 3J). We assayed each of these model systems
(manipulated lines derived from H1299 cells and U2OS cells)
for clonogenicity and anchorage-independent growth. We
observed that NOVA1 knockdown was not bypassed by forced
hTERT expression in the H1299 cells with NOVA1 knockdown at
population doubling 60 (Supplementary Figure 3H). The H1299
cells with the combination of hTERT expression and NOVA1
knockdown formed fewer colonies in both assays of growth
compared to H1299 cells with control shRNA and hTERT
expression (both the NOVA1 knockdown and the NOVA1
knockdown with hTERT expression formed about 50% fewer
colonies in the colongenicity assay and 40–50% fewer colonies in
the anchorage-independent soft agar growth assay; Supplemen-
tary Figure 3H and I). Interestingly, upon hTERT overexpression
the levels of NOVA1 increased in both the shRNA control and
shRNA NOVA1 lines. This observation can indicate at least two
possibilities; either a hypermorphic phenotype where TERT is
acting in a way it normally would not due to the high expression
levels or that a regulatory loop exists between NOVA1 and
hTERT. Further, ALT cells with control shRNAs grew substan-
tially better in both growth assays compared to NOVA1 shRNA
cells, forming about twice as many colonies in both assays as well
(Supplementary Figure 3K and L). This indicates that beyond the
control of telomerase activity and hTERT splicing in cancer cells,
NOVA1 is independently involved in pathways related to
tumorigenesis and clonogenic growth.
NOVA1 confers a growth and survival advantage of tumor
cells. To determine if cell lines with high or low levels of NOVA1
formed tumors in vivo, we injected cells into both hind ﬂanks of
immunocompromised mice. We observed three out of four
injections of H920 shRNA control cells formed tumors in vivo
while only one of four injections of H920 NOVA1 knockdown
cells formed tumors (Fig. 3c, d). The tumors derived from the
control cell lines were signiﬁcantly larger compared to the single
tumor derived from the NOVA1 knockdown cells. This indicates
that NOVA1 knockdown in H920 cells signiﬁcantly altered the
ability of these lung cancer cells to form tumors in vivo. Further,
we injected mice with Calu6 control lentiviral vector cells (a cell
line that does not express NOVA1) and compared it to Calu6
cells with ectopic expression of NOVA1. We monitored the
tumors for a period of 4 weeks and observed that NOVA1-
expressing cells formed bigger tumors compared to the control
Calu6 cells (Fig. 3e, f). Similar to the knockdown experiment, the
NOVA1 expression conferred a growth advantage in vivo over
cells that lacked NOVA1.
NOVA1 interacts with hTERT pre-mRNA. NOVA1 binds to
pre-mRNAs in a sequence-dependent fashion, binding to YCAY
(Y= C or U) motifs in RNAs37. First, we looked in silico at the
hTERT locus for YCAY motifs, focusing on sequences (including
introns and exons) from exons 5 to 10 (Fig. 4a). It is not possible
to use previous public HITS-CLIP databases from mice because of
sequence element differences between mice and humans13. Since
NOVA1 is known to bind to clusters of YCAY motifs we looked
for areas of highly concentrated motifs. We found several
potential candidate regions in hTERT exons and introns 5
through 10 (Fig. 4a). We performed ultraviolet (UV)-crosslinking
and immunoprecipitation (UV-IP)38 of H1299 cells and observed
an enrichment of the NOVA1:hTERT RNA interaction in hTERT
intron 8 (direct repeat 8, DR8). NOVA1 appeared to bind in a
region we previously observed to be involved in the regulation of
hTERT alternative splicing (Fig. 4a–c)13. Our working model is
that NOVA1 binds to the DR8 region and promotes splicing of
hTERT to include RT domain-coding exons 7 and 8. This idea is
consistent with previous observations suggesting that NOVA1
can act as a splicing enhancer if it binds following an alternatively
spliced exon39. From in silico analysis we found that DR8 of
hTERT, a 258-base pair element, contains 7 YCAY NOVA1-
binding motifs. Previously, we found that when cells were treated
with a 2-O-methyl-antisense oligonucleotide to this region,
hTERT minus beta splicing was increased and FL splicing was
reduced, supporting the idea that a factor that promotes inclusion
of hTERT exons 7 and 8 was blocked13. This is consistent with
our observations that hTERT minus beta splicing increases when
NOVA1 levels are reduced. To conﬁrm the UV-IP observations,
we utilized our hTERT minigene series that we previously
developed, which excludes DR8, the intron 8 region containing
the NOVA1-binding motifs, and performed crosslinking and
immunoprecipitation followed by RT-ddPCR (CLIP-ddPCR)
(Fig. 4d). As additional controls, we included constructs that
contained or excluded a highly similar (85% homology) sequence
region in intron 6 called direct repeat 6 (DR6; Fig. 4e). Interest-
ingly, DR6, a 254-base pair region in intron 6, contains fewer
YCAY (5) motifs than DR8. When DR8 was present we could
effectively pull down hTERT minigene pre-mRNAs, but we could
not when DR8 was absent. As a control, we also assayed our CLIP
cDNAs for a known NOVA1 target gene, glycine receptor alpha 2
(GLRA2)40. As previously described GLRA2 exon 3A and 3B are
mutually exclusive exons regulated by NOVA1. First, we tested
for expression of GLRA2 mutually exclusive exon 3A and 3B
usage in HeLa and H1299 cancer cells (Supplementary Figure 4C
and E), and observed that exon 3B of GLRA2 was preferentially
used in cancer cells. Next, we looked in our H1299 NOVA1 rescue
series to see if GLRA2 was regulated by NOVA1 in cancer cells
and indeed found that GLRA2 exon 3B is preferentially used
when NOVA1 levels are higher (Supplementary Figure 4D)
similar to previous studies40. Next, we assayed our CLIP cDNAs
and observed that GLRA2 was effectively pulled down in all
extracts regardless of hTERT status, indicating that our CLIP was
efﬁcient (Supplementary Figure 4E). To further conﬁrm the CLIP
and UV-IP observations, we in vitro transcribed a 1 kb fragment
of RNA containing DR8 of hTERT intron 8 and performed an
RNA pull-down assay (Fig. 4f). When we expressed NOVA1 in
293 cells and exposed the lysate to the labeled RNA, we observed
effective pull down of NOVA1 (Fig. 4g). These data indicated that
NOVA1 was binding to this 1 kb RNA fragment of hTERT intron
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05582-x ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3112 | DOI: 10.1038/s41467-018-05582-x | www.nature.com/naturecommunications 7
8. Since a 1 kb RNA fragment may bind many proteins, we
generated a series of smaller (~150 nt) RNA baits surrounding
and in DR8 of hTERT to more speciﬁcally determine where
NOVA1 was binding. We observed binding to oligos 3, 4, and 5
(Fig. 4h) and weak to no binding to oligos 1 and 2 (Fig. 4h), with
the strongest binding to oligo 3 in the 5′ end of DR8. We
hypothesize that NOVA1 is binding to DR8 and the region sur-
rounding DR8 of hTERT through both direct and indirect
interactions (that is, as part of a splicing factor complex) that
directs NOVA1’s impact on hTERT splicing. There are 7 YCAY
hTERT minigene pre-mRNA with potential NOVA1-binding sites and CLIP primers
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motifs in DR8 (oligos 3 and 4), oligo 5, which is 71 nts 3′ of DR8
contains an additional 2 YCAY motifs. We hypothesize that a
complex of proteins, including NOVA1, that interact at or near
DR8 could be pulling down NOVA1 with oligo 5, explaining why
NOVA1 is present in oligo 5’s pull down. Overall, our results are
consistent with the model that when NOVA1 is bound to hTERT
mRNAs in intron 8, it acts as a splicing enhancer, promoting the
inclusion of exons 7 and 8 to increase the production of FL
hTERT mRNAs.
Deletion or mutation of NOVA1 binding shifts hTERT spli-
cing. To further deﬁne the importance of hTERT DR8 in telomere
biology, we deleted a 480-nt fragment of hTERT intron 8 using
two CRISPR guide RNAs ﬂanking DR8 (Fig. 5a). We identiﬁed
three H1299 clones that had the correct on-target deletion of
hTERT intron 8 DNA containing DR8 (Supplementary Fig-
ure 5A, B and C). In a parallel experiment, we introduced either
wild-type (WT) or mutant DR8 DNA via a donor plasmid with
CRISPR/Cas9 (Fig. 5b). The mutant donor plasmid had all seven
of the YCAY motifs in DR8 mutated to YAAY, which has pre-
viously been shown to block NOVA1 recognition of target
genes34. We identiﬁed 5 clones with homozygous integration of
the mutant NOVA1-binding sites and sorted an additional 6
single-cell WT clones to control for heterogeneity of tumor cell
lines41 (Supplementary Figure 5E). This produced 15 cell lines (14
clones and the parental H1299 population) that we then followed
over time for telomere length, telomerase activity, and TERT
splicing phenotypes.
We observed clonal heterogeneity for telomere length between
all the clones, including the control clones, as expected. In the
sorted control clones, however, we observed minimal telomere
length changes over time (14 ± 4.4 nts per doubling; average ±
standard deviation), while signiﬁcant telomere shortening was
observed in both DR8 YAAY mutant clones (46 ± 42 nts per
doubling; p= 0.05) and in the DR8-deleted clones (108 ± 45 nts
per doubling; p < 0.001) (Fig. 5c). All the DR8-deleted clones had
longer telomeres on average compared to the mutant DR8 clones.
Thus, deletion of DR8 may produce a strong selection pressure
for clones with longer telomeres. hTERT splicing was also
signiﬁcantly changed, with a dramatic shift toward spliced
products (35% FL in sorted controls versus 12% FL in DR8
YAAY mutants, p < 0.001, Student’s t; Fig. 5d, Supplementary
Figure 5G). Further, we assayed telomerase enzyme activity over
time at three different population doublings and observed that on
average, the DR8 YAAY mutants had 70% less telomerase activity
compared to the controls while the DR8 deletion clones had
nearly undetectable telomerase activity (Fig. 5f, Supplementary
Figure 5G). The telomere shortening rates of 46 nts per doubling
and 107 nts per cell doubling in the DR8 mutants (70%
telomerase inhibition) and DR8-deleted clones (nearly 100%
telomerase inhibition) correlate closely with observations that
telomerase adds 50–150 nts per cell division to maintain
telomeres42.
We also observed clonal heterogeneity for hTERT splicing as
shown in Fig. 5e: three clones had mostly minus beta, one clone
had higher levels of hTERT FL and total hTERT mRNA, which
correlated to higher telomerase activity (DR8 mutant 5), and one
clone seemed to lack all transcripts with exons 5–9 (DR8 mutant
3, Supplementary Figure 5G and H). The clone (DR8 mutant 3)
that completely lacked mRNA containing hTERT exons 5–9 also
had no detectable telomerase activity (via TRAP) and eventually
died in culture at population doubling 58 post sorting. Further,
only one of three DR8-deleted clones showed FL hTERT message
and telomerase activity (DR8 deletion 2, Supplementary Figure 5G
and H). After long-term passage one of the DR8 deletion clones
stopped dividing at PD 85 (DR8 deletion 1). We measured the
expression level of NOVA1 mRNA in these clones and observed
that on average the clones were similar for NOVA1 mRNA
expression levels (Supplementary Figure 5I), however we
observed heterogeneity in expression between clones with
different telomere biology phenotypes. For example, the deletion
clone that died (DR8 deletion 1) and the mutant clone that died
had low expression of NOVA1 compared to the average
(Supplementary Figure 5). In contrast, the DR8 deletion clones
with telomerase activity (DR8 deletion 2) had very high NOVA1
levels. This suggests that NOVA1 may help to maintain
telomerase levels via an alternative binding site that promotes
hTERT FL splicing. Overall, these data solidify the role of DR8 in
the splicing choice of hTERT to produce FL or spliced products.
To determine if DR8 was important only in cell lines with
NOVA1 or as a general splicing enhancer region, we compared
the response of H1299 cells (cells that express NOVA1) and
Calu6 cells (cells lacking NOVA1 expression) following treatment
of an antisense oligonucleotide that blocks a sequence 19 nts from
the 5′ end of DR8 (including a YCAY element, antisense oligo
called, “DR8+ 19”) and was previously shown to shift hTERT
splicing toward minus beta containing transcripts in a Hela cell
clone that expresses NOVA113. H1299 cells treated with 50 nM of
DR8+ 19 antisense oligo for 48 h signiﬁcantly shifted hTERT
splicing toward minus beta while Calu6 cells treated did not shift
the splicing of hTERT (Supplementary Figure 5J and K). This
indicates that DR8 is likely only an important splicing enhancer
region in hTERT when NOVA1 is present.
Discussion
The catalytic protein component of telomerase, hTERT, is spliced
into multiple isoforms, but only FL hTERT mRNA is capable of
producing enzymatically active protein that can maintain telo-
meres13. We observed that ~70% of the non-small cell lung
cancers tested here express moderate to high levels of NOVA1.
NOVA1 expression promotes the inclusion of exons 7 and 8 in
the RT domain of hTERT to produce enzymatically active telo-
merase and regulate telomere length (Fig. 6). Further, NOVA1
Fig. 4 NOVA1 binds to a deep intronic element in TERT precursor RNAs. a Cartoon of TERT exons 5 through 10 showing potential NOVA1-binding sites and
the primers (blue boxes) used in the ultraviolet immunoprecipitation (UV-IP) procedure. b UV-IP procedure schematic showing the major steps. c Droplet
digital RT-PCR showing UV-IP enrichment of NOVA1 at TERT DR8 (n= 3 independent IPs). d Schematic of UV-crosslinking immunoprecipitation (CLIP)
droplet digital PCR procedure. e Cartoon of hTERT minigenes used in the CLIP experiments, primers (light blue boxes), and droplet digital PCR
quantiﬁcation of NOVA1 protein and TERT RNA interaction (n= 3 independent IPs). Differences in constructs are highlighted in red and dark blue boxes and
text. The minigenes where plasmid DNA was removed to generate the different constructs lacking the direct repeat regions are shown by a broken line.
f Schematic of RNA bait procedure to ﬁnd proteins that interact with hTERT RNAs. A second set of RNA baits were made from PCR fragments of hTERT
intron 8 around and including DR8. g We in vitro transcribed a 1 kb fragment of hTERT intron 8 that contained DR8. Western blot and quantiﬁcation of
western showing pull down of NOVA1 protein with TERT RNA containing DR8 (n= 2). h Representative western blot of NOVA1 protein showing binding to
DR8 at baits (oligos) 3, 4, and 5 (n= 2). Data are expressed as means and standard error of the mean where applicable. *p < 0.05. Supplementary data
associated with this ﬁgure can be found in Supplementary Figure 4
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Fig. 5 Deletion of DR8 or mutation of NOVA1-binding sites in TERT shortens telomeres. a Schematic of CRISPR/Cas9 strategy to delete DR8 in TERT intron 8.
b Schematic of CRISPR/Cas9 strategy to mutate NOVA1-binding sites in TERT DR8. c Terminal restriction fragment length (TRF-Southern blot) analysis of
parental, sorted controls, DR8 NOVA1 ’7 × YAAY’ mutants, and DR8-deleted H1299 clones. *DR8 mutant 3 and *DR8 deletion 1 stopped growing at population
doubling 57 and 85, respectively. d hTERT splicing isoform proportion analysis of parental, averaged sorted controls (n= 6), averaged DR8 mutants (n= 5), and
averaged DR8 mutants (n= 3). e hTERT splicing isoform proportion analysis of averaged sorted controls (n= 6), averaged DR8 mutants (n= 5), and averaged
DR8 mutants (n= 3). This plot shows the clonal heterogeneity of hTERT splicing in the clones used in this experiment. Standard deviation of the group means
displays the variation in the response to mutation or deletion of direct repeat 8 (DR8) in hTERT. Only sorted controls and clones are shown as variation in the
parental line is shown elsewhere. f Telomerase activity of parental, averaged controls (n= 6), averaged DR8 mutants (n= 5), and averaged DR8 deletion clones
(n= 3). Data are expressed as means and standard deviation where applicable. *p < 0.05. Supplementary data associated with this ﬁgure can be found in
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may be a regulator of growth and invasion-related signaling in
cancer cells, coupling telomere length maintenance to other
cancer cell characteristics (Fig. 3). Thus, the applicability of the
hTERT minigene screen data we have compiled represents a
valuable resource that could be mined to identify other splicing
factors that could be targeted in cancer.
These studies extend earlier ﬁndings that RNA metabolism is a
regulatory component of telomerase activity and telomere length
maintenance43,44. For instance, the mRNA decay pathway was
found to be critical in telomere length maintenance in yeast45.
Additionally, our splicing factor screen and the work of others
point to the importance of hnRNP proteins in telomere biology
and in the regulation of hTERT pre-mRNA splicing46–51 (Fig. 1).
We conﬁrmed factors that were previously reported to directly
bind to hTERT pre-mRNA and regulate minus beta splice choice
(SRSF11, hnRNPH2, and hnRNPL)15. We observed signiﬁcant
changes in the minigene reporter assay for hnRNPH1, hnRNPF,
and hnRNPM, which were all observed to potentially bind hTERT
pre-mRNAs in CLIP experiments52, further validating the mini-
gene data. As far as we could determine, this is the ﬁrst study to
investigate knockdown of splicing factors in human cancer cells
with regard to telomere biology and we observed that even
modest knockdown is compatible with long-term tissue culture
studies to investigate changes in the telomere length of cells.
During the generation of CRISPR/Cas9 clones of H1299 lung
cancer cells some striking and unexpected phenotypes arose upon
mutation and deletion of DR8 in hTERT. Two clones that
eventually died off in culture had about 2 kb telomere lengths
when they died (DR8 mutant clone 3 and DR8 deletion clone 1).
However, DR8 mutant clone 4 had a mean telomere length of
about 2 kb and survived in culture (Fig. 5). We speculate that the
telomere DNA damage sensing capabilities between the clones
that died compared to the clones that survived at these short
telomere lengths are different. Further, DR8 mutant clone 3 and
DR8 deletion clone 1 both lacked expression of hTERT exons 5–9,
while DR8 mutant clone 4 had a small amount of FL hTERT
remaining (Fig. 5). This small amount of hTERT FL could have
generated enough active telomerase to maintain the short telo-
meres. We speculate DR8 mutant clone 4 could have had
recruitment and processivity advantages compared to other lines
Model of hTERT splicing regulation by DR8 in NOVA1 + and NOVA1 – cells:
Model A – NOVA1 binding to DR8 acts as a splicing enhancer to include exons 7/8,
promoting the production of FL hTERT mRNAs
Model  of hTERT splicing regulation by DR8 in NOVA1 + and NOVA1 – cells:
Model B – TERT RNA:RNA pairing of VNTR6 with complimentary sequence in intron 8 generates
secondary structure favoring skipping of exons 7/8 but NOVA1 disrupts this secondary structure
and promotes inclusion of exons 7/8
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with higher telomerase activity but increased rates of telomere
shortening. These clones could be useful in future studies aiming
at elucidating the genetic and molecular underpinnings of these
less-well-described phenomena.
We propose two models for how the NOVA1 protein is
interacting with TERT pre-mRNAs (Fig. 6). In the ﬁrst model
only considering NOVA1 protein’s inﬂuence on hTERT pre-
mRNAs, we propose that NOVA1 binds to DR8, recruiting the
basal exon junction recognition machinery that promotes the use
of exon 8’s 5′ splice donor with exon 9’s 3′ splice acceptor site to
generate hTERT mRNAs, including exons 7 and 8 (Fig. 6a). In the
second model, we consider both pre-mRNA secondary structures
and NOVA1 proteins. We previously deﬁned a role for RNA:
RNA pairing in regulating minus beta splice choice14. In this
model (Fig. 6b), RNA:RNA pairing of a variable nucleotide tan-
dem repeat in intron 6 of hTERT creates an RNA secondary
structure that brings the exon 6 5′ splice site in close proximity to
the exon 9 3′ splice site, generating a structural change where
joining of exon 6 to exon 9 is favored over exon 6 to exon 7,
producing the minus beta splice variant over FL mRNAs. When
NOVA1 is present and bound to DR8, this disrupts the secondary
structure created by RNA:RNA pairing between intron 6 and
intron 8 and brings the exon 8 5′ splice site closer to the exon 9 3′
splice site thus producing more FL molecules of hTERT compared
to cells lacking NOVA1 (Fig. 6b). Supporting this model, when
DR8 is deleted or all seven YCAY motifs in DR8 are mutated
three lines switched their splicing to almost solely minus beta
(Supplementary Figure 5). In one DR8 mutant (clone 3) and one
DR8 deletion (clone 1) we observed a complete loss of expression
of hTERT exons 5–9 (Supplementary Figure 5). One possibility is
that the loss of NOVA1 binding in these clones leads to a change
in secondary structure in the pre-mRNA of hTERT and results in
a complete skipping of exons 5–9 but that other regions of hTERT
are still expressed (Supplementary Figure 5H).
The present studies add to the growing body of literature that
alternative splicing may be targetable in cancer53. The present study
points out that telomerase activity and telomere length maintenance
can be manipulated by targeting the alternative splicing machinery.
We chose to follow-up on NOVA1, a well-deﬁned splicing factor
that has implications in cancer biology as well, because it had
binding sites in hTERT introns and exons, and because it displays
cancer cell-speciﬁc expression across a wide variety of human tis-
sues (Fig. 1, besides neurons and testis). In addition to NOVA1’s
role in neurons, NOVA1 can also have a role in the survival of
cancer cells (Fig. 3). It is unlikely that NOVA2 is playing a similar
role in cancer biology as it is only expressed in brain cancers and
absent in nearly all other human tumors (http://www.proteinatlas.
org/ENSG00000104967-NOVA2/cancer).
It is clear that NOVA1 has additional targets in cancer cells
that are related to the growth phenotypes observed herein.
NOVA1 may regulate AKT levels inﬂuencing growth and survival
of cancer cells. The role of AKT in cell proliferation and survival
is well documented and several anticancer drugs are currently in
use that target AKT. Further, AKT is upstream of FOXO tran-
scription factors, which controls cell survival and apoptosis. AKT
functions in cellular survival by phosphorylating and sequestering
FOXO’s in the cytoplasm and keeping them inactive and unable
to initiate transcription of the cell death program. When NOVA1
levels are reduced, AKT protein levels are reduced32, FOXO’s
become active and initiate transcription of the cellular death
machinery. Future studies investigating the role of NOVA1 in
AKT induced cancer cell survival are warranted. Further, AKT is
also a kinase that may increase the nuclear pool of TERT proteins
and thus increase the potential for active telomere length main-
taining telomerase54. Thus, a NOVA1-AKT-TERT axis may exist
in some cancers that may be targetable.
Overall, our results are consistent with the idea that hTERT
splicing is malleable in cancer cells by either targeting the intronic
DR8 region or by targeting NOVA1. While NOVA1 impacts
hTERT pre-mRNAs, it also has other targets in cancer cells.
Further studies will be required to determine if NOVA1 is indeed
clinically targetable in cancer, including the identiﬁcation of
proteins that interact with NOVA1 and the genes that NOVA1
regulates in cancer. In summary, NOVA1 appears to integrate
replicative immortality (telomerase activity and telomere length
maintenance), with sustained proliferative signaling, invasion,
and metastasis. Thus, the present studies have provided new
insights into hTERT regulation and identiﬁed NOVA1 as a lead
candidate gene for development of small-molecule inhibitors
targeting the splicing machinery for anticancer therapy.
Methods
Plasmids. Human telomerase (hTERT) exon and intron sequences were inserted
into pcDNA5/FRT expression vector (Invitrogen, Carlbad, CA) and were modiﬁed
to exclude exons 5 and 10 and introns 5 and 9 to shorten the construct13. The
hTERT minigene was modiﬁed with renilla and ﬁreﬂy luciferase fragments. The
minigene was integrated into a single locus using previously described meth-
ods13,14. We modiﬁed the previously used minigene to include a renilla (Rluc) and
a ﬁreﬂy luciferase (Fluc) gene. We fused renilla luciferase and E2A (equine rhinitis
A virus 2A) peptide in frame to hTERT exon 8 so that when exon 8 was included in
the minigene pre-mRNA, the protein product would produce Rluc (Fig. 1a) putting
the Fluc out of frame. Conversely, when exons 7 and 8 are skipped and splicing
occurs from exon 6 to exon 9, Fluc and a T2A (Thosea asigna virus 2A) peptide are
in frame. The use of the 2A peptides facilitated the generation of equal molar ratios
of luciferase to hTERT55. Lentiviral plasmid for secreted embryonic alkaline
phosphatase (SEAP, Clontech) Lentiviral GFP pGIPZ shRNA plasmids for control
(non-targeting), NOVA1 (Openbiosystems, NOVA1–5′-TTGGACTTAGACAG
CTTGA) were obtained. Lentivirus was made by co-transfecting 5 μg of proviral
shRNA plasmids and 2 μg of packaging plasmids pMD2.G and psPAX2 using
Polyjet transfection reagent (SignaGen Laboratories) into 293FT cells. CCSB-Broad
lentiviral human NOVA1 FL cDNA with a C-terminal V5 tag and blasticidin
selection in mammalian cells (accession: BC075038, clone ID:
ccsbBroad304_01104) was purchased and sequence veriﬁed by our group (GE,
Dharmacon). Viral particles were produced as above. ShRNA-resistant NOVA1
cDNA was generated by site-directed mutagenesis (Agilent Quickchange). Retro-
viral particles were generated in 293FT packaging cells with pUMVC and pVSVG.
Plasmids for CRISPR/Cas9 experiments are described below in the genome engi-
neering section.
Cell culture and cell lines. All non-small cell lung cancer cell lines (H1299, H920,
Calu6, and H2882) were cultured at 37 °C in 5% CO2 in 4:1 DMEM:Medium 199
containing 10% calf serum (HyClone, Logan, UT). Brieﬂy, HBECs were maintained
in low oxygen conditions in serum-free media containing supplements from the
Keratinocyte-SFM media (Invitrogen/Gibco catalog # 17005-42) on a collagen/
gelatin-coated tissue culture dish56. All cell lines were obtained from American
Type Culture Collection, or as a kind gift from Drs. John Minna and Adi Gazdar.
Cancer growth assays. Stable knockdown cells and controls (non-targeting
shRNA) were suspended in 0.375% Noble agar (Difcon, Detroit) in supplemented
basal medium at two densities (1000 and 2000 cells) and overlaid on 0.75% Noble
agar in 24-well plates. Each density was seeded in triplicate and each assay was
performed twice. Colony formation efﬁciency was calculated by the average
number of colonies counted per cell divided by the number of cells seeded.
Colonies larger than 0.1 mm were measured and counted after 10 days of growth
and the average of the counts was used. Data are plotted as fold change over non-
targeting shRNA cells. Data were analyzed with two-tailed Student’s t tests57.
Invasion was determined using Boyden chamber assays. Brieﬂy, cells were
serum starved overnight (~16 h) prior to assays for invasion. Twenty-four-well
Matrigel-coated transwell ﬁlters (BD Biosciences, San Jose, CA) were thawed and
rehydrated according to the manufacturer’s instructions. Cells were collected and
re-suspended in serum-free media and added to the top chamber in duplicate. The
bottom chamber was ﬁlled with 2% serum-containing media (4:1 DMEM:Medium
199) as a chemoattractant. Cells were incubated overnight. Non-invaded cells were
scraped off with a cotton swab and wells were washed with phosphate-buffered
saline (PBS). Invaded cells were ﬁxed for 5 min with 10% neutral buffered formalin
and stained for 10 min with Hoechst (Invitrogen). Images were taken at ×10
magniﬁcation58.
For colony formation assays, cells were plated at clonal density (30–70 cells per
2.5 cm2 dish) in 10% serum-containing media. Cells were analyzed 7 days after
plating by staining with Hoechst (Invitrogen)59.
To test the dependence of observed growth defects on telomere length and
telomerase activity, an hTERT cDNA (pMIN-Ub-IRES-Blast lentiviral vector from
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ref. 36) was transdued into H1299 cells with control shRNAs or NOVA1 shRNA
after 50 population doublings. This vector contains a 3.398 kb cDNA of hTERT
coding sequence thus no splicing is needed to make hTERT mRNA. Further
information about the hTERT cDNA from pGRN145 that was inserted into a
lentiviral vector can be found here (https://www.atcc.org/Products/All/MBA-141.
aspx#generalinformation). It is clear that TERT RT domain was expressed in our
experiments and that telomerase was active (see Supplementary Figure 5).
Following infection and selection, cells were plated as described above in the cancer
growth assays.
Xenograft. All animal experiments were approved by the University of Texas
Southwestern (UTSW) Institutional Animal Care and Use Committee (IACUC)
and conducted as per the institutional guidelines. Athymic NRC nu/nu nude mice
(~4–6 weeks old, Charles River) were purchased. Tissue culture cells from H920
control shRNA, H920 NOVA1 shRNA, Calu6 control (WT with empty lentiviral
vector), and Calu6 plus NOVA1 cDNA were cultured and injected subcutaneously
into the hind ﬂanks. For H920 cells 5 million cells in 100 μL of 1× PBS were
injected. For Calu6 cell 1 million cells in 100 μL of 1× PBS were injected. Tumor
growth was monitored by caliper measurement once or twice weekly. Tumor
volume was calculated (volume= (width)2 × length/2).
Transient siRNA experiments. For transient knockdown experiments cells were
plated in six-well plates (150 000 cells per well) and were transfected with non-
silencing controls (Santa Cruz Biotechnology, sc-37007) or a pool of three siRNAs
targeting NOVA1 (Santa Cruz Biotechnology, sc-42142: sense RNA sequences—(1)
5′-GACAGACAAUUGUUCAGUUtt-3′, (2) 5′-GAACGGUUGAAGCACU-
GAAtt-3′, (3) 5′-GACCACCGUUAAUCCAGAUtt-3′). Cells were plated 24 h
prior to transfections. On the day of transfection, media was switched to 2% serum
and transfection complexes were prepared with 50 nM of siRNAs using MEM
(Gibco, Invitrogen) and RNAi max (Invitrogen) following the manufacturer’s
procedures. Following 72 h of exposure to siRNAs cells were washed, trypsinized,
counted, and pelleted for RNA extraction and telomerase activity assays. We
treated normal BJ ﬁbroblasts three times (every 96 h) with non-targeting control or
NOVA1 targeting siRNAs over the course of 12 days, counted the cells, and
determined viability with trypan blue staining.
Western blot analysis. Total protein lysates were extracted from tissue culture
cells using Laemmli buffer, boiled, and the protein concentration determined (BCA
protein assay, Pierce). Thirty micrograms of protein was resolved on SDS-
polyacrylamide gel electrophoresis gels, transferred to polyvinylidene ﬂuoride
membranes, and detected with a rabbit monoclonal antibody for NOVA1 (Abcam,
EPR13847, ab183024, 1:1000 dilution in 5%BSA)). Protein loading was determined
with antibodies against with beta actin (Sigma; 1: 20 000 dilution in 5% non-fat dry
milk) or histone H3 (Sigma; 1:1000 in 5% non-fat dry milk). Uncropped images of
all western blots can be found in Supplementary Figure 7.
RT-droplet digital PCR. Tissue panel RNAs were purchased (Clontech, 20 tissue
panel II). Three sets of cDNAs were made with a 1:1 mixture of random hexamer
and oligo-dT priming with three different RTs: (1) iScript advanced (42 °C, Bio-
Rad); (2) Superscript III (55 °C, Invitrogen); and (3) AMV (50 °C, Invitrogen). All
RNA samples were spiked with a known amount of MS2 bacteriophage RNA to
enable normalization of absolute molecule counts from ddPCR. For tissue panel
hTERT and NOVA1 mRNA analysis we used three RTs because we observed
differences in detection of hTERT using different RTs so to be able to eliminate
spurious measures of low abundance targets we averaged data for all three RTs. All
cDNAs were diluted 1:4 before use and stored at −80 °C. For hTERT splicing
analyses we used iScript Advanced (Bio-Rad) to generate cDNAs, diluted 1:4, and
used within 48 h of production in ddPCR measures. Primer sequences for TERT
are listed in Supplementary Table 2. Uncropped gel images of RT-PCR gels can be
found in Supplementary Figure 7.
Droplet digital TRAP assay (telomerase activity). Quantitation of telomerase
enzyme activity was performed using a modiﬁed telomeric repeat ampliﬁcation
protocol23. Brieﬂy, cells were lysed, diluted, and added to the telomerase extension
reaction for 40 min followed by heat inactivation of telomerase. An aliquot of the
extension products was ampliﬁed in a ddPCR for 40 cycles and ﬂuorescence
measured and droplets read and counted on the droplet reader (QX200, Bio-Rad).
Following, data were processed and telomerase extension products per cell
equivalents determined.
Telomere length analysis. The average length of telomeres (terminal restriction
fragment lengths) was measured as described in ref. 60 with the following mod-
iﬁcations. DNA was transferred to Hybond-N+ membranes (GE Healthcare,
Piscataway, NJ) using vacuum transfer. The membrane was brieﬂy air-dried and
DNA was ﬁxed by UV-crosslinking. Membranes were then probed for telomeres
using a digoxigenin (DIG)-labeled telomere probe, detected with an horeseradish
peroxidase-linked anti-DIG antibody (Roche), and exposed with CDP-star
(Roche)61. Uncropped scans of Southern blot images can be found in Supple-
mentary Figure 7.
Minigene screen setup and reporter assays. We used two databases (NCBI gene
and Genecards) and searched the key words of “RNA binding protein” and
“splicing factor” to generate a list of 516 genes (Supplementary Data ﬁle 1) and
then ordered pools of four siRNAs to each gene (Dharmacon, GE, sequences of
pools to each gene are located in Supplementary Data ﬁle 1, we had 528 pools of
siRNA as several genes had multiple siRNA pools). HeLa cells harboring the
hTERT minigene splicing reporter were plated and transfected 24 h later with 1 nM
of each individual pool of siRNAs. A low concentration of siRNAs (1 nM) helped
to reduce the potential viability effects and “off-target” effects. Plates were trans-
fected using RNAi max (Invitrogen; sequences in Supplementary Data ﬁle 1) and
cells were analyzed 72 h following transfection. As negative controls, we used a pool
of scrambled siRNAs (siRNA control), a transfection control (cells, transfection
reagents, and media), and a “cells only” control (cells plus culture media).
Knockdown of the core splicing factor hnRNPH1 resulted in a fourfold induction of
minus beta splicing in the minigene luciferase assay (p < 0.05, Student’s t; Sup-
plementary Figure 1A). hnRNPH1 was included as a minus beta inducing positive
control and ubiquitin (UBB) as a transfection-positive control. Cells were lysed in
passive lysis buffer and analyzed for renillia and ﬁreﬂy luciferase following the
manufacturer’s instructions after 72 h (Dual-luciferase reporter assay system,
Promega). The screen was repeated twice and data were averaged for each luci-
ferase measurement. Then, a ratio of minus beta to FL splice variants were cal-
culated for each target gene. Each ratio was then expressed relative to the ratio of
the siRNA control (set to a value of 1). Since many RNA-processing factors have
documented effects on cell viability, we also infected cells with a SEAP reporter
lentivirus. Only living cells will produce and secrete SEAP. Thus, we used SEAP as
a viability control (Supplementary Figure 1B). Conditioned media (20 μL from the
siRNA-transfected cells) was analyzed for SEAP (Great EscAPe SEAP Chemilu-
minescence kit). As shown in Supplementary Figure 1B, siRNA depletion of UBB
resulted in a loss of cell viability compared to the “cells only” condition. SEAP data
were used following identiﬁcation of a splicing hit to determine if the change in
hTERT splicing reporter ratio was due to changes in cell viability.
Ultraviolet immunoprecipitation RT-PCR. UV-IP was performed as described38
with slight modiﬁcations. Brieﬂy, 90% conﬂuent cells were crosslinked with UV-C
(254 nm, 250 mj cm−2), scrapped, washed, and pelleted. Pellets were then lysed in
RIPA buffer containing an RNase inhibitor (Ambion), mixed with antibodies
conjugated to magnetic beads (rabbit IgG or rabbit monoclonal NOVA1, Abcam,
EPR13847, ab183024), and washed. RNA was extracted and RT-ddPCR performed
with a series of primers designed near and around the in silico-identiﬁed potential
NOVA1-binding sites (Fig. 4a, b).
Crosslinking immunoprecipitation RT-ddPCR. To perform CLIP we UV (UV-C,
254 nm, 250mj cm−2)-crosslinked cells in 15 cm dishes with 3 mL 1× PBS. A
volume of 7 mL of ice-cold 1× PBS was added to the crosslinked cells and the cells
were scrapped and collected by centrifugation (4 °C, 0.2 × g for 5 min). Supernatant
was removed and 1 mL of ice-cold 1× PBS was added and the cells spun and pelleted
a second time in a 1.5mL microcentrifuge tube. The cells were lysed in 0.5% SDS
lysis buffer (Tris-HCl, pH 7, 1 mM EDTA, 1 mM dithiothreitol, RNase inhibitor
(Ambion), and 1 mM phenylmethylsulfonyl ﬂuoride; 140 μL per sample) and heated
to 65 °C for 5 min and immediately placed on ice for 5 min. The lysate was volume
corrected to 700 μL in RIPA correction buffer (1.25% NP40, 0.625% sodium
deoxycholate, 62.5 mM Tris-HCl, pH 8, 2.25mM EDTA, 187.5 mM NaCl, RNase
inhibitor (Ambion), and 1 mM phenylmethylsulfonyl ﬂuoride; 560 μL per sample).
The lysate (700 μL) was then passed over a Qiashredder® column twice (centrifuged
for 30 s at 13 000 × g at 4 °C). The entire lysate was then centrifuged for 15min at
16 000 × g at 4 °C and the supernatant transferred to a new microcentrifuge tube.
The lysates were then treated with micrococcal nuclease (0.15 U in 50mM CaCl2
buffer for 10min at 37 °C), immediately placed on ice, and 20mM EGTA added to
quench the micrococcal nuclease activity. Antibodies and beads were prepared at
room temperature in sodium phosphate buffer (0.1 M, pH 8.1; Anti-Nova1 antibody
[EPR13847] (ab183024), Abcam; Rabbit IgG) and mixed with magnetic protein A/G
beads (Dynabeads, 50 μL per sample) and added to the cleared lysate. The samples
(NOVA1 or IgG) were immunoprecipitated at 4 °C for 4 h. The samples were then
washed ﬁve times in RIPA buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS,
150mM NaCl, Tris-HCl, pH 8, and 2 mM EDTA). After the ﬁnal wash the bead-
protein-RNA complexes were re-suspended in 200 μL of RIPA buffer and 2 U of
RNase-free DNase (Ambion) was added in 300 μL of DNase buffer and incubated
for 10min at 37 °C with gentle agitation. Beads were collected with the magnet and
supernatant removed. Proteinase K buffer was added (0.5mgmL−1 proteinase K,
0.5% SDS, 20mM Tris-HCl, pH 7.5, 5 mM EDTA, 8 ng of MS2 RNA, and 5 μL of
MRC RNA precipitation carrier; 300 μL per sample) and incubated at 37 °C for
15 min with shaking. RNA was then precipitated with sodium acetate and phenol
chloroform. Following RNA precipitation reverse transcription was performed with
Superscirpt III® (Invitrogen) with random hexamers. ddPCR was performed with
Evagreen®.
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RNA pull down with biotinylated RNA baits. A plasmid was generated (TOPO
TA) via PCR from a BAC containing hTERT (RP11-990A6, CHORI) using primers
that generated a 1 kb fragment of hTERT intron 8 including DR8. Following
integration into the TOPO TA vector, in vitro transcription was performed using
the T7 promoter (Ampliscribe T7 kit, Ambion, Life technologies) following the
manufacturer’s instructions, including a 45 min DNase step prior to RNA pre-
cipitation. RNA was isolated and biotinylated at the 3′ end (Pierce RNA 3′ end
biotinylation kit). Biotinylated RNA was puriﬁed with streptavidin beads. Cell
lysates were prepared following the kit instructions (Peirce Magnetic RNA-protein
pull-down kit). Protein-RNA complexes were immunoblotted for NOVA1 fol-
lowing pull down. To produce the smaller RNA baits, T7 promoter sequences were
incorporated into the 5′ end of the forward primers of each region of interest in
and surrounding hTERT DR8. The same procedure was followed as above to
generate the RNA baits. In both cases 293FT cells were transfected with V5-tagged
NOVA1 cDNA construct using lipofectamine 2000. After 48 h, triplicate samples of
10 × 106 cell were washed, typisinized, counted, pelleted, and frozen at −80 °C until
analysis.
Genome-editing and engineering methods (CRISPR/Cas9 methods). To delete
hTERT DR8 we designed two guide RNAs (pre-DR8 guide—5′-ATCTGCTTGC
GTTGACTCGC-3′ and post DR8: 5′-TTATTTTCGGGAAGCGCTAT-3′) and
cloned these guides into PX458 (Addgene Plasmid #48138—pSpCas9(BB)-2A-
GFP). Cells were transfected using Lipofectamine 3000® following the manu-
facturer’s instructions for scaling up to 10 cm dish. Forty-eight hours after trans-
fection cells were ﬂow sorted for the top 5% green ﬂuorescent protein (GFP)-
positive cells into individual wells of a 96-well plate. After about 14 days wells with
growing cells were scaled up to a six-well plate and once conﬂuent scaled up to a
10 cm dish. Cells were collected for DNA extraction and genotype analysis of
CRISPR mutation validation. To validate the deletion the 480-base pair sequence
containing DR8 of hTERT, we performed PCR with two different primer sets of
different sizes to ensure our results were robust. We also isolated the PCR product
from primer set two and performed Sanger sequencing to verify the recombination
event was between two TERT alleles and not a different sequence in the genome.
To mutate endogenous hTERT we had two plasmids synthesized (SGI-DNA).
The WT plasmid (WT–hTERT intron 8 mutant PAM in pUC-SGI) contained 2000
bases of hTERT intron 8 surrounding DR8 that had the PAM sequence of the post-
DR8 guide above mutated from 5′-CCT to ACT. The mutant plasmid (MUT-
7 × “YAAY” DR8 MUT hTERT mutant PAM in pUC-SGI) was identical to the WT
plasmid except that we mutated all seven of the “YCAY” motifs in DR8 to “YAAY”
(changing the central CA to AA is known to block NOVA1 recognition34). We then
co-transfected the guide RNA post DR8 and either WT or MUT plasmid in the
presence or absence of NHEJ inhibitor SRC7-pyrazine. We pre-treated cells with
50 nM SCR7 for 30 min prior to transfection. Cells were transfected with
Lipofectamine 3000® and 48 h later the top 5% GFP-positive cells were sorted as
above. Once wells with growing cells were identiﬁed we scaled up the clones as
above. We isolated DNA from the clones to validate the insertion of WT or MUT
plasmids. To validate WT insertion clones, we used PCR to amplify a sequence
surrounding DR8 and puriﬁed and sequenced the PCR product via Sanger
sequencing. To screen and validate MUT clones, we used PCR to amplify a region
around DR8 and then digested the DNA with BclI. Conveniently, the mutations in
DR8 (YCAY sites 4 and 5) introduced a novel restriction enzyme site that allowed
us to identify mutant clones via PCR and REN digestion (similar to RFLP analysis,
Supplementary Figure 5D, E, and F). We also Sanger sequence validated the MUT
clones. We were able to validate two WT DR8 clones with homozygous PAM
sequence mutation, indicating that homologous recombination of the donor
plasmid was successful. We were also able to validate that 5 clones had
homozygous integration of mutant DR8. We also sorted a variety of controls
(vector only and one control exposed to both Cas9 and mutant donor that failed to
undergo cutting and homology directed (HR) repair, “failed HR control”) since it is
well established that clonal heterogeneity exists in tumor cells lines41. These clones
were all validated by PCR and Sanger sequencing to have WT DR8 hTERT
sequences (representative Sanger sequencing in Supplementary Figure 5E). This
produced 15 cell lines (14 clones and the parental H1299 population) that we then
followed over time for telomere length, telomerase activity, and TERT splicing
phenotypes.
Study approval. All animal experiments were approved by the UTSW IACUC and
conducted as per institutional guidelines.
Statistics. Unless otherwise noted in the Methods section, ﬁgure legend, or in the
Results section, pairwise Student’s t tests (two-sided) were used to determine sta-
tistically signiﬁcant differences between group means. Signiﬁcant differences were
accepted at a p value < 0.05. For analysis of microarray data, we correlated the
expression data of 528 RNA-binding proteins across six cell lines (differential
expression analysis (t tests) and false-discovery rate corrected with Benjamini-
Hochberg procedure).
Data availability. The datasets generated during and/or analyzed during the
current study are available in the GEO repository under accession number
GSE32036. All other data that support the ﬁndings of this study are available from
the corresponding author upon reasonable request.
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